APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hypereosinophilic Syndrome Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Hypereosinophilic Syndrome Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025182 pages

Choose your research edition.

Industry ResearchHypereosinophilic Syndrome Drug Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Hypereosinophilic Syndrome Drug Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Hypereosinophilic Syndrome Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hypereosinophilic Syndrome Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Hypereosinophilic Syndrome Drug Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Hypereosinophilic Syndrome Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Hypereosinophilic Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hypereosinophilic Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hypereosinophilic Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Hypereosinophilic Syndrome Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Hypereosinophilic Syndrome Drug include GlaxoSmithKline Plc, Stemline Therapeutics Inc, Kyowa Hakko Kirin Co Ltd, Knopp Biosciences LLC and Bristol-Myers Squibb Co, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Hypereosinophilic Syndrome Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hypereosinophilic Syndrome Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hypereosinophilic Syndrome Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hypereosinophilic Syndrome Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Hypereosinophilic Syndrome Drug Segment by Company

GlaxoSmithKline Plc

Stemline Therapeutics Inc

Kyowa Hakko Kirin Co Ltd

Knopp Biosciences LLC

Bristol-Myers Squibb Co

Hypereosinophilic Syndrome Drug Segment by Type

Dexpramipexole Dihydrochloride

Mepolizumab

Dasatinib

Benralizumab

Others

Hypereosinophilic Syndrome Drug Segment by Application

Clinic

Hospital

Research Center

Hypereosinophilic Syndrome Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hypereosinophilic Syndrome Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hypereosinophilic Syndrome Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hypereosinophilic Syndrome Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hypereosinophilic Syndrome Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Hypereosinophilic Syndrome Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Hypereosinophilic Syndrome Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Hypereosinophilic Syndrome Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Hypereosinophilic Syndrome Drug Industry Trends Table 2. Hypereosinophilic Syndrome Drug Industry Drivers Table 3. Hypereosinophilic Syndrome Drug Industry Opportunities and Challenges Table 4. Hypereosinophilic Syndrome Drug Industry Restraints Table 5. Global Hypereosinophilic Syndrome Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Hypereosinophilic Syndrome Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Hypereosinophilic Syndrome Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Hypereosinophilic Syndrome Drug Sales Market Share by Manufacturers Table 9. Global Hypereosinophilic Syndrome Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Hypereosinophilic Syndrome Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Hypereosinophilic Syndrome Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Hypereosinophilic Syndrome Drug Manufacturers, Product Type & Application Table 13. Global Hypereosinophilic Syndrome Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Hypereosinophilic Syndrome Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Dexpramipexole Dihydrochloride Table 17. Major Manufacturers of Mepolizumab Table 18. Major Manufacturers of Dasatinib Table 19. Major Manufacturers of Benralizumab Table 20. Major Manufacturers of Others Table 21. Global Hypereosinophilic Syndrome Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Hypereosinophilic Syndrome Drug Sales by Type (2021-2026) & (K Units) Table 23. Global Hypereosinophilic Syndrome Drug Sales by Type (2027-2032) & (K Units) Table 24. Global Hypereosinophilic Syndrome Drug Sales Market Share by Type (2021-2026) Table 25. Global Hypereosinophilic Syndrome Drug Sales Market Share by Type (2027-2032) Table 26. Global Hypereosinophilic Syndrome Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Hypereosinophilic Syndrome Drug Revenue by Type (2021-2026) & (K Units) Table 28. Global Hypereosinophilic Syndrome Drug Revenue by Type (2027-2032) & (K Units) Table 29. Global Hypereosinophilic Syndrome Drug Revenue Market Share by Type (2021-2026) Table 30. Global Hypereosinophilic Syndrome Drug Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Clinic Table 32. Major Manufacturers of Hospital Table 33. Major Manufacturers of Research Center Table 34. Global Hypereosinophilic Syndrome Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Hypereosinophilic Syndrome Drug Sales by Application (2021-2026) & (K Units) Table 36. Global Hypereosinophilic Syndrome Drug Sales by Application (2027-2032) & (K Units) Table 37. Global Hypereosinophilic Syndrome Drug Sales Market Share by Application (2021-2026) Table 38. Global Hypereosinophilic Syndrome Drug Sales Market Share by Application (2027-2032) Table 39. Global Hypereosinophilic Syndrome Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Hypereosinophilic Syndrome Drug Revenue by Application (2021-2026) & (K Units) Table 41. Global Hypereosinophilic Syndrome Drug Revenue by Application (2027-2032) & (K Units) Table 42. Global Hypereosinophilic Syndrome Drug Revenue Market Share by Application (2021-2026) Table 43. Global Hypereosinophilic Syndrome Drug Revenue Market Share by Application (2027-2032) Table 44. Global Hypereosinophilic Syndrome Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Hypereosinophilic Syndrome Drug Sales by Region (2021-2026) & (K Units) Table 46. Global Hypereosinophilic Syndrome Drug Sales Market Share by Region (2021-2026) Table 47. Global Hypereosinophilic Syndrome Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Hypereosinophilic Syndrome Drug Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Hypereosinophilic Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Hypereosinophilic Syndrome Drug Sales by Country (2021-2026) & (K Units) Table 51. North America Hypereosinophilic Syndrome Drug Sales by Country (2027-2032) & (K Units) Table 52. Europe Hypereosinophilic Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Hypereosinophilic Syndrome Drug Sales by Country (2021-2026) & (K Units) Table 54. Europe Hypereosinophilic Syndrome Drug Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Hypereosinophilic Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Hypereosinophilic Syndrome Drug Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Hypereosinophilic Syndrome Drug Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Hypereosinophilic Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Hypereosinophilic Syndrome Drug Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Hypereosinophilic Syndrome Drug Sales by Country (2027-2032) & (K Units) Table 61. Global Hypereosinophilic Syndrome Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Hypereosinophilic Syndrome Drug Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Hypereosinophilic Syndrome Drug Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Hypereosinophilic Syndrome Drug Revenue Market Share by Region (2021-2026) Table 65. Global Hypereosinophilic Syndrome Drug Revenue Market Share by Region (2027-2032) Table 66. GlaxoSmithKline Plc Company Information Table 67. GlaxoSmithKline Plc Business Overview Table 68. GlaxoSmithKline Plc Hypereosinophilic Syndrome Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. GlaxoSmithKline Plc Hypereosinophilic Syndrome Drug Product Portfolio Table 70. GlaxoSmithKline Plc Recent Development Table 71. Stemline Therapeutics Inc Company Information Table 72. Stemline Therapeutics Inc Business Overview Table 73. Stemline Therapeutics Inc Hypereosinophilic Syndrome Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Stemline Therapeutics Inc Hypereosinophilic Syndrome Drug Product Portfolio Table 75. Stemline Therapeutics Inc Recent Development Table 76. Kyowa Hakko Kirin Co Ltd Company Information Table 77. Kyowa Hakko Kirin Co Ltd Business Overview Table 78. Kyowa Hakko Kirin Co Ltd Hypereosinophilic Syndrome Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Kyowa Hakko Kirin Co Ltd Hypereosinophilic Syndrome Drug Product Portfolio Table 80. Kyowa Hakko Kirin Co Ltd Recent Development Table 81. Knopp Biosciences LLC Company Information Table 82. Knopp Biosciences LLC Business Overview Table 83. Knopp Biosciences LLC Hypereosinophilic Syndrome Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Knopp Biosciences LLC Hypereosinophilic Syndrome Drug Product Portfolio Table 85. Knopp Biosciences LLC Recent Development Table 86. Bristol-Myers Squibb Co Company Information Table 87. Bristol-Myers Squibb Co Business Overview Table 88. Bristol-Myers Squibb Co Hypereosinophilic Syndrome Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Bristol-Myers Squibb Co Hypereosinophilic Syndrome Drug Product Portfolio Table 90. Bristol-Myers Squibb Co Recent Development Table 91. Key Raw Materials Table 92. Raw Materials Key Suppliers Table 93. Hypereosinophilic Syndrome Drug Distributors List Table 94. Hypereosinophilic Syndrome Drug Customers List Table 95. Research Programs/Design for This Report Table 96. Authors List of This Report Table 97. Secondary Sources Table 98. Primary Sources List of Figures Figure 1. Hypereosinophilic Syndrome Drug Product Image Figure 2. Global Hypereosinophilic Syndrome Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hypereosinophilic Syndrome Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Hypereosinophilic Syndrome Drug Sales (2021-2032) & (K Units) Figure 5. Global Hypereosinophilic Syndrome Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Hypereosinophilic Syndrome Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Dexpramipexole Dihydrochloride Image Figure 9. Mepolizumab Image Figure 10. Dasatinib Image Figure 11. Benralizumab Image Figure 12. Others Image Figure 13. Global Hypereosinophilic Syndrome Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Hypereosinophilic Syndrome Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Hypereosinophilic Syndrome Drug Sales Market Share by Type (2021-2032) Figure 16. Global Hypereosinophilic Syndrome Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Hypereosinophilic Syndrome Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Hypereosinophilic Syndrome Drug Revenue Market Share by Type (2021-2032) Figure 19. Clinic Image Figure 20. Hospital Image Figure 21. Research Center Image Figure 22. Global Hypereosinophilic Syndrome Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Hypereosinophilic Syndrome Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Hypereosinophilic Syndrome Drug Sales Market Share by Application (2021-2032) Figure 25. Global Hypereosinophilic Syndrome Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Hypereosinophilic Syndrome Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Hypereosinophilic Syndrome Drug Revenue Market Share by Application (2021-2032) Figure 28. North America Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Hypereosinophilic Syndrome Drug Sales Market Share by Country (2021-2032) Figure 30. U.S. Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Hypereosinophilic Syndrome Drug Sales Market Share by Country (2021-2032) Figure 35. Germany Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Hypereosinophilic Syndrome Drug Sales Market Share by Country (2021-2032) Figure 42. China Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Hypereosinophilic Syndrome Drug Sales Market Share by Country (2021-2032) Figure 50. Brazil Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Hypereosinophilic Syndrome Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Hypereosinophilic Syndrome Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Hypereosinophilic Syndrome Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Hypereosinophilic Syndrome Drug Revenue (2021-2032) & (US$ Million) Figure 61. North America Hypereosinophilic Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Hypereosinophilic Syndrome Drug Revenue (2021-2032) & (US$ Million) Figure 63. Europe Hypereosinophilic Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Hypereosinophilic Syndrome Drug Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Hypereosinophilic Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Hypereosinophilic Syndrome Drug Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Hypereosinophilic Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Hypereosinophilic Syndrome Drug Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Hypereosinophilic Syndrome Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Dexpramipexole Dihydrochloride
  • Mepolizumab
  • Dasatinib
  • Benralizumab
  • Others
Applications
  • Clinic
  • Hospital
  • Research Center
Companies covered
  • GlaxoSmithKline Plc
  • Stemline Therapeutics Inc
  • Kyowa Hakko Kirin Co Ltd
  • Knopp Biosciences LLC
  • Bristol-Myers Squibb Co

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Hypereosinophilic Syndrome Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Hypereosinophilic Syndrome Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Hypereosinophilic Syndrome Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Hypereosinophilic Syndrome Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Hypereosinophilic Syndrome Drug Market Dynamics
  1. 2.1 Hypereosinophilic Syndrome Drug Industry Trends
  2. 2.2 Hypereosinophilic Syndrome Drug Industry Drivers
  3. 2.3 Hypereosinophilic Syndrome Drug Industry Opportunities and Challenges
  4. 2.4 Hypereosinophilic Syndrome Drug Industry Restraints
3 Hypereosinophilic Syndrome Drug Market by Manufacturers
  1. 3.1 Global Hypereosinophilic Syndrome Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Hypereosinophilic Syndrome Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Hypereosinophilic Syndrome Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Hypereosinophilic Syndrome Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Hypereosinophilic Syndrome Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Hypereosinophilic Syndrome Drug Manufacturers, Product Type & Application
  7. 3.7 Global Hypereosinophilic Syndrome Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Hypereosinophilic Syndrome Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Hypereosinophilic Syndrome Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Hypereosinophilic Syndrome Drug Tier 1, Tier 2, and Tier 3
4 Hypereosinophilic Syndrome Drug Market by Type
  1. 4.1 Hypereosinophilic Syndrome Drug Type Introduction
  2. 4.1.1 Dexpramipexole Dihydrochloride
  3. 4.1.2 Mepolizumab
  4. 4.1.3 Dasatinib
  5. 4.1.4 Benralizumab
  6. 4.1.5 Others
  7. 4.2 Global Hypereosinophilic Syndrome Drug Sales by Type
  8. 4.2.1 Global Hypereosinophilic Syndrome Drug Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Hypereosinophilic Syndrome Drug Sales by Type (2021-2032)
  10. 4.2.3 Global Hypereosinophilic Syndrome Drug Sales Market Share by Type (2021-2032)
  11. 4.3 Global Hypereosinophilic Syndrome Drug Revenue by Type
  12. 4.3.1 Global Hypereosinophilic Syndrome Drug Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Hypereosinophilic Syndrome Drug Revenue by Type (2021-2032)
  14. 4.3.3 Global Hypereosinophilic Syndrome Drug Revenue Market Share by Type (2021-2032)
5 Hypereosinophilic Syndrome Drug Market by Application
  1. 5.1 Hypereosinophilic Syndrome Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Research Center
  5. 5.2 Global Hypereosinophilic Syndrome Drug Sales by Application
  6. 5.2.1 Global Hypereosinophilic Syndrome Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hypereosinophilic Syndrome Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Hypereosinophilic Syndrome Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Hypereosinophilic Syndrome Drug Revenue by Application
  10. 5.3.1 Global Hypereosinophilic Syndrome Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Hypereosinophilic Syndrome Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Hypereosinophilic Syndrome Drug Revenue Market Share by Application (2021-2032)
6 Global Hypereosinophilic Syndrome Drug Sales by Region
  1. 6.1 Global Hypereosinophilic Syndrome Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hypereosinophilic Syndrome Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Hypereosinophilic Syndrome Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Hypereosinophilic Syndrome Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Hypereosinophilic Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Hypereosinophilic Syndrome Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Hypereosinophilic Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Hypereosinophilic Syndrome Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Hypereosinophilic Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Hypereosinophilic Syndrome Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Hypereosinophilic Syndrome Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Hypereosinophilic Syndrome Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Hypereosinophilic Syndrome Drug Revenue by Region
  1. 7.1 Global Hypereosinophilic Syndrome Drug Revenue by Region
  2. 7.1.1 Global Hypereosinophilic Syndrome Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Hypereosinophilic Syndrome Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Hypereosinophilic Syndrome Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Hypereosinophilic Syndrome Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Hypereosinophilic Syndrome Drug Revenue (2021-2032)
  8. 7.2.2 North America Hypereosinophilic Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Hypereosinophilic Syndrome Drug Revenue (2021-2032)
  11. 7.3.2 Europe Hypereosinophilic Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Hypereosinophilic Syndrome Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Hypereosinophilic Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Hypereosinophilic Syndrome Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Hypereosinophilic Syndrome Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 GlaxoSmithKline Plc
  2. 8.1.1 GlaxoSmithKline Plc Company Information
  3. 8.1.2 GlaxoSmithKline Plc Business Overview
  4. 8.1.3 GlaxoSmithKline Plc Hypereosinophilic Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GlaxoSmithKline Plc Hypereosinophilic Syndrome Drug Product Portfolio
  6. 8.1.5 GlaxoSmithKline Plc Recent Developments
  7. 8.2 Stemline Therapeutics Inc
  8. 8.2.1 Stemline Therapeutics Inc Company Information
  9. 8.2.2 Stemline Therapeutics Inc Business Overview
  10. 8.2.3 Stemline Therapeutics Inc Hypereosinophilic Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Stemline Therapeutics Inc Hypereosinophilic Syndrome Drug Product Portfolio
  12. 8.2.5 Stemline Therapeutics Inc Recent Developments
  13. 8.3 Kyowa Hakko Kirin Co Ltd
  14. 8.3.1 Kyowa Hakko Kirin Co Ltd Company Information
  15. 8.3.2 Kyowa Hakko Kirin Co Ltd Business Overview
  16. 8.3.3 Kyowa Hakko Kirin Co Ltd Hypereosinophilic Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Kyowa Hakko Kirin Co Ltd Hypereosinophilic Syndrome Drug Product Portfolio
  18. 8.3.5 Kyowa Hakko Kirin Co Ltd Recent Developments
  19. 8.4 Knopp Biosciences LLC
  20. 8.4.1 Knopp Biosciences LLC Company Information
  21. 8.4.2 Knopp Biosciences LLC Business Overview
  22. 8.4.3 Knopp Biosciences LLC Hypereosinophilic Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Knopp Biosciences LLC Hypereosinophilic Syndrome Drug Product Portfolio
  24. 8.4.5 Knopp Biosciences LLC Recent Developments
  25. 8.5 Bristol-Myers Squibb Co
  26. 8.5.1 Bristol-Myers Squibb Co Company Information
  27. 8.5.2 Bristol-Myers Squibb Co Business Overview
  28. 8.5.3 Bristol-Myers Squibb Co Hypereosinophilic Syndrome Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bristol-Myers Squibb Co Hypereosinophilic Syndrome Drug Product Portfolio
  30. 8.5.5 Bristol-Myers Squibb Co Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hypereosinophilic Syndrome Drug Value Chain Analysis
  2. 9.1.1 Hypereosinophilic Syndrome Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hypereosinophilic Syndrome Drug Production Mode & Process
  6. 9.2 Hypereosinophilic Syndrome Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hypereosinophilic Syndrome Drug Distributors
  9. 9.2.3 Hypereosinophilic Syndrome Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst